Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
- PMID: 14711538
- DOI: 10.1016/j.fertnstert.2003.10.004
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
Abstract
Since the 1990 National Institutes of Health-sponsored conference on polycystic ovary syndrome (PCOS), it has become appreciated that the syndrome encompasses a broader spectrum of signs and symptoms of ovarian dysfunction than those defined by the original diagnostic criteria. The 2003 Rotterdam consensus workshop concluded that PCOS is a syndrome of ovarian dysfunction along with the cardinal features hyperandrogenism and polycystic ovary (PCO) morphology. PCOS remains a syndrome, and as such no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis. Its clinical manifestations may include menstrual irregularities, signs of androgen excess, and obesity. Insulin resistance and elevated serum LH levels are also common features in PCOS. PCOS is associated with an increased risk of type 2 diabetes and cardiovascular events.
Similar articles
-
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).Hum Reprod. 2004 Jan;19(1):41-7. doi: 10.1093/humrep/deh098. Hum Reprod. 2004. PMID: 14688154 Review.
-
Adolescents diagnosed with polycystic ovary syndrome under the Rotterdam criteria but not meeting the diagnosis under the updated guideline.Hum Reprod. 2024 May 2;39(5):1072-1077. doi: 10.1093/humrep/deae042. Hum Reprod. 2024. PMID: 38514450
-
Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.J Clin Endocrinol Metab. 2006 Mar;91(3):781-5. doi: 10.1210/jc.2005-2153. Epub 2006 Jan 17. J Clin Endocrinol Metab. 2006. PMID: 16418211
-
Best methods for identification and treatment of PCOS.Minerva Ginecol. 2010 Feb;62(1):33-48. Minerva Ginecol. 2010. PMID: 20186113 Review.
-
Polycystic ovary syndrome in adolescents.Best Pract Res Clin Endocrinol Metab. 2019 Jun;33(3):101272. doi: 10.1016/j.beem.2019.04.006. Epub 2019 Apr 13. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 31027973 Review.
Cited by
-
Fixed versus flexible gonadotropin releasing hormone antagonist protocol in women with polycystic ovary syndrome undergoing in vitro fertilization: An RCT.Int J Reprod Biomed. 2024 Oct 14;22(8):617-626. doi: 10.18502/ijrm.v22i8.17230. eCollection 2024 Aug. Int J Reprod Biomed. 2024. PMID: 39494117 Free PMC article.
-
Understanding Pain in Polycystic Ovary Syndrome: Health Risks and Treatment Effectiveness.medRxiv [Preprint]. 2024 Oct 16:2024.10.15.24315513. doi: 10.1101/2024.10.15.24315513. medRxiv. 2024. PMID: 39484281 Free PMC article. Preprint.
-
Altered bile acids profile is a risk factor for hyperandrogenism in lean women with PCOS: a case control study.Sci Rep. 2024 Oct 31;14(1):26215. doi: 10.1038/s41598-024-77645-7. Sci Rep. 2024. PMID: 39482365 Free PMC article.
-
Contribution of cervical incompetence to occurrence of second trimester abortion in patients with polycystic ovary syndrome during the frozen embryo transfer cycle.Front Endocrinol (Lausanne). 2024 Oct 16;15:1411618. doi: 10.3389/fendo.2024.1411618. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39479270 Free PMC article.
-
GDF-15 levels in patients with polycystic ovary syndrome treated with metformin: a combined clinical and in silico pathway analysis.Arch Endocrinol Metab. 2024 Aug 27;68:e230416. doi: 10.20945/2359-4292-2023-0416. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39420932 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
